ESC 365 - Interleukin-6 as a potential biomarker of cancer therapy-related cardiac dysfunction: A comparative analysis with myeloperoxidase and tumor necrosis factor-alpha.

Delegates Premium Access

Interleukin-6 as a potential biomarker of cancer therapy-related cardiac dysfunction: A comparative analysis with myeloperoxidase and tumor necrosis factor-alpha.

Session: Poster session (2)

Topic: Stratification, Prevention and Monitoring

Speaker: Doctor A. Borowiec (Warsaw, PL)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Doctor Anna Borowiec

National Institute of Oncology, Warsaw, Poland, Warsaw (Poland)

0 follower

59 more presentations in this session

Temporal trends and emerging burden of cardiovascular disease in cancer patients: A nationwide study from 2005 to 2022

Speaker: Doctor J. Cho (Seoul, KR)

Cardiovascular risk factors in oncology: A cross-sectional analysis of patients undergoing chemo-radiotherapy at a tertiary care center

Speaker: Doctor M. Canavera Ibanez (Bogota, CO)

Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy

Speaker: Doctor A. Spannbauer (Vienna, AT)

Cardiovascular toxicity prediction in breast cancer patients: the HFA/ICOS risk tool in real-world practice

Speaker: Doctor B. Andrade (Santarem, PT)

Use of CMR in the assessment of cardiovascular reserve in patients treated with CAR-T therapy

Speaker: Doctor B. Aumente Rodriguez (Salamanca, ES)

Access the full session

Poster session (2)

Speakers: Doctor A. Borowiec, Doctor J. Cho, Doctor M. Canavera Ibanez, Doctor A. Spannbauer, Doctor B. Andrade...

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources